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Abstract
Dopamine (DA) agonists are widely used as primary treatments for Parkinson’s
disease. However, they do not prevent progressive degeneration of dopaminer-
gic neurons, the central pathology of the disease. In this study, we found that
subcutaneous injection of a cytokine mixture containing granulocyte macrophage
colony-stimulating factor and interleukin-3 (IL-3) markedly suppressed dopamin-
ergic neurodegeneration in 6-hydroxydopamine-lesioned rats, an animal model of
Parkinson’s disease. The cytokine mixture suppressed the decrease of DA content
inthestriatum,andamelioratedmotorfunctioninthelesionedrats.Inresponseto
thecytokineinjection,dopaminergicneuronsinthesubstantianigraparscompacta
increased expression of the antiapoptotic protein Bcl-xL. Microglial activation in
the pars compacta was evident in both the saline- and cytokine-injected rats. How-
ever,thecytokinemixturesuppressedexpressionoftheproinﬂammatorycytokines
IL-1β and tumor necrosis factors α, and upregulated the neuroprotective factors
insulin-like growth factor-1 and hepatocyte growth factor. Similar responses were
observedinculturedmicroglia.DetailedmorphometricanalysesrevealedthatNG2
proteoglycan-expressing glial cells increased in the cytokine-injected rats, while as-
trocytic activation with increased expression of antioxidative factors was evident
only in the saline-injected rats. Thus, the present ﬁndings show that the cytokine
mixture was markedly effective in suppressing neurodegeneration. Its neuropro-
tective effects may be mediated by increased expression of Bcl-xL in dopaminergic
neurons, and the activation of beneﬁcial actions of microglia that promote neu-
ronal survival. Furthermore, this cytokine mixture may have indirect actions on
NG2 proteoglycan-expressing glia, whose role may be implicated in neuronal sur-
vival.
Introduction
Parkinson’s disease (PD) is a very common neurodegenera-
tive disorder, which is characterized by resting tremor, im-
paired balance and coordination, bradykinesia, and rigidity.
The main pathology of PD is progressive degeneration of
dopaminergic (DArgic) neurons in the substantia nigra, pars
compacta (SNpc). DArgic neurodegeneration results in de-
creased dopamine (DA) content in the striatum, which is the
major cause of motor disability in PD. Therefore, current
PD treatments are mostly focused on replenishing DArgic
activity in the striatum by administering L-DOPA or other
DA agonists to PD patients. However, this type of therapy
does not suppress the DArgic neurodegeneration. Therefore,
noveltreatmentsarebeingsoughtthatmitigateneuronalloss
in PD (Yacoubian and Standaert 2009).
In addition to neurodegeneration, glial cell activation has
been shown as a pathologic feature of PD (Mosley et al.
2006;McGeerandMcGeer2008;TanseyandGoldberg2010).
Therefore, it is speculated that treatments that affect glial
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function in the SNpc can lead to novel PD treatments. There
are four types of glial cells in the SNpc: astrocytes, microglia,
oligodendrocytes, and NG2 glia. The NG2 glia are glial cells
speciﬁcally expressing NG2 chondroitin sulphate proteogly-
can, and are, at least in part, precursor cells for oligodendro-
cytes. NG2 glia are sometimes also called NG2 cells, synan-
tocytes,andpolydendrocytes (Buttetal. 2005;Staugaitisand
Trapp 2009; Trotter et al. 2010).
In response to neuronal injuries, astrocytes become acti-
vated, increase their expression of glial ﬁbrillary acidic pro-
tein (GFAP), and migrate to the sites of injury. At this point,
theyarecalledreactiveastrocytes,andformastroglialscarsin
and around the injury sites. In PD, the accumulationof reac-
tive astrocytes in the SNpc is well documented (McGeer and
McGeer 2008; Asanuma et al. 2010; Choudhury et al. 2011).
Although the actions of reactive astrocytes on neuronal sur-
vivalhavenotyetbeenfullyelucidated,itisbelievedthatthey
possess neuroprotective attributes, which have mainly been
observedininvitroexperiments(Tanakaetal.1999;Miyazaki
et al. 2011). The neuroprotective actions of astrocytes have
beenattributedtotheirantioxidantdefensemechanisms,and
their ability to secrete a variety of neuroprotective factors,
such as glial cell-line-derived neurotrophic factor (GDNF)
(Schaar et al. 1993) and brain-derived neurotrophic factor
(BDNF) (Dreyfus et al. 1999). Because of the presumed neu-
roprotective role of astrocytes, agents targeting these cells
have been proposed to suppress DArgic neurodegeneration
(Asanuma et al. 2010; Choudhury et al. 2011).
Microglia play pivotal roles in immune reactions in
the brain. Microglial cells are mesodermal in origin with
macrophage-likeproperties(Kreutzberg1996).PDhassome
features in common with neuroinﬂammatory diseases, be-
cause it is characterized by the presence of activated mi-
croglia in the SNpc (Mosley et al. 2006; McGeer and McGeer
2008; Long–Smith et al. 2009; Tansey and Goldberg 2010).
Similar neuroinﬂammatory reactions may be critical in an-
other major neurodegenerative disorder Alzheimer’s disease
(Lue et al. 2010) and therefore microglia should be the ther-
apeutic targets to suppress neurodegeneration (Yacoubian
and Standaert 2009). However, in contrast to astrocytes, the
majority appears to support the notion that microglia are
detrimental to the disease (Liberatore et al. 1999; Block et al.
2007; Henry et al. 2009; Marinova–Mutafchieva et al. 2009),
as they are known to produce proinﬂammatory cytokines,
such as interleukin-1β (IL-1β)a n dt u m o rn e c r o s i sf a c t o r s
α (TNFα) (Long–Smith et al. 2009; De Lella Ezcurra et al.
2010), and increase oxidative stress (Liberatore et al. 1999;
Levesque et al. 2010). Thus, astrocytes and microglia have
often been implicated in the pathogenesis of PD. On the
other hand, NG2 glia and oligodendrocytes have also been
shown to abundantly exist in the SNpc, whereas very lit-
tle is known about their roles in PD (McGeer and McGeer
2008).
A cytokine mixture of granulocyte macrophage colony-
stimulating factor (GM-CSF) and IL-3 has been found of
its much stronger ameliorative effect on the stab-wounded
rat brains than the solely used GM-CSF or IL-3 (Nishihara
et al. 2011). In the present study, the cytokine mixture ef-
fectively prevented 6-hydroxydopmaine (6-OHDA)-induced
neurodegenerationintheSNpc,whichisananimalmodelof
Parkinsonism.Theﬁndingssuggestthattheeffectsaremedi-
ated by increased expression of prosurvival proteins, and the
differential activities of neuroinﬂammatory cells, including
NG2glia,whoserolemaybeimplicatedinneuronalsurvival.
Materials and Methods
Animals
Adult male Wistar rats, weighing 220–250 g, were housed
under standard laboratory conditions. The animals were al-
lowed free access to food and water throughout the experi-
ments. The rats were kept in a 12/12 h dark/light cycle. All
animal experiments were carried out in accordance with the
Guidelines for Animal Experimentation of Ehime University
Graduate School of Medicine.
6-OHDA treatment and cytokine injection
Animals were kept under pentobarbital sodium anesthe-
sia (50 mg/kg) and placed in a stereotactic instrument
(Narishige, Tokyo, Japan). 6-OHDA (Sigma, St. Louis, MO)
was dissolved in saline containing ascorbic acid (Wako,
Osaka, Japan) (10 μg/μL dissolved in 1% ascorbate-saline),
kept on ice (4◦C) and protected from light to minimize ox-
idation, until use. The rats were then given uni- or bilateral
injectionsof6-OHDA.Unilateralinjectionwasemployedfor
immunohistochemical analyses, and bilateral injection was
used for all other studies. For unilateral injection, 5 μLo f
6-OHDA was drawn into a Hamilton syringe and then in-
jectedintotherightsideofthestriatum,throughaholemade
on the skull at 1 mm anterior to bregma and 3 mm lateral
from the midline. The depth of the needle tip was 5 mm
f r o mt h es k u l ls u r f a c e .T h es a m ea m o u n to f6 - O H D Aw a s
injected into the left side of the striatum for bilateral injec-
tion. The rate of ﬂuid injection was 1 μL /min. The needle
was left at the point of injection for an additional 10 min
after the injection and then slowly withdrawn. Because the
bilaterally injected rats could not move well to drink or to
eat,theywereintraperitoneallyinjectedwithelectrolytesolu-
tion(Solita-T3,Ajinomoto,Tokyo,Japan)twiceperdayfor1
week.Acytokinemixturecontaining0.2mg/mLratrecombi-
nant GM-CSF (PeproTech, London, UK) and 0.2 mg/mL rat
recombinant IL-3 (PeproTech) was subcutaneously injected
from the next day of the 6-OHDA-treatment at a dose of
10 μg/kg body weight (Nishihara et al. 2011). For the con-
trol,thesameamountofsalinewassubcutaneouslyinjected.
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Determination of DA content in the striatum
The DA content in the striatum was measured by high-
performance liquid chromatography (HPLC) (Yabe et al.
2009). Both sides of the striatum were dissected out and
quickly put on an ice-cold glass plate and stored at −80◦C
until assayed. The striatum samples from both sides were in-
dependently homogenized with an ultrasonic cell disruptor
( T o m yS e i k o ,T o k y o ,J a p a n )i n0 . 1Mp e r c h l o r i ca c i dc o n -
taining 5 mM EDTA (Wako) and 3,4-dihydroxybenzamine
(Wako), and were centrifuged. A 10-μL aliquot of the ﬁl-
tered supernatant was injected into a HPLC apparatus with a
reversed-phase column. The mobile phase consisted of 15%
(v/v)methanolcontaining0.1Msodiumacetate(Wako)and
0.1 M citric acid (Wako), adjusted to pH 3.5, with 180 mg/L
sodiumoctydylsulphate(Wako),and10mMEDTA,pumped
through the column at a rate of 0.25 mL/min. The data from
the right and left striatum were averaged and processed for
statistical analysis.
Rota-rod test
Motorcoordinationandbalanceweretestedusingarota-rod
(Ugo Basile, Rota-rod 7750, Italy) before administration of
drugs, and 7, 14, 21, 28, and 56 days after administration of
the drugs. The rota-rod test was performed by placing the
rat on a rotating drum and measuring the time each animal
was able to maintain its balance while attempting to walk
on top of the rod (Dekundy et al. 2007). The test was done
between 1400 h and 1500 h. Animals were pretrained twice
a day, 3 days before the test. The speed of the rota-rod was
maintained ﬁxed at 40 rpm over a 300-s period. The animals
were touched on their tails several times in each session to
maintain a high degree of alertness in the test. The rota-rod
performance was expressed in seconds; namely the amount
of time the animals remained on the rotating rod.
Quantitative real-time reverse
transcriptase-polymerase chain reaction
(qRT-PCR)
Therightsideventralmidbraincontainingthesubstantiani-
gra (midbrain delineated longitudinally 4.5 to 6.6 mm from
bregma, perpendicularly under 7 mm from the skull) was
d i s s e c t e do u ta t7d a y sa f t e r6 - O H D A - t r e a t m e n ta n ds t o r e d
at −80◦C until assayed. Tissue samples were homogenized
in ISOGEN (Nippon gene, Tokyo, Japan) using an ultrasonic
celldisruptor.Then,theirtotalRNAwascollected.cDNAwas
obtainedfromDNase-I-treatedRNAbyreversetranscription
usinganoligo-(dT)15primer,aspreviouslydescribed(Taka-
hashi et al. 2008). cDNA samples were prepared from seven
separate samples of brain tissue astrocytes and microglia.
Quantitativereal-timereversetranscriptasePCR(qRT-PCR)
analysis was performed in triplicate using a MJ mini instru-
ment(BioRad,Hercules,CA)usingFastStartUniversalSYBR
Table 1. Oligonucleotide primers for real-time RT-PCR
Gene Sense/anti-sense
β-Actin 5 -AGA AGA GCT ATG AGC TGC CTG ACG-3 
5 -TAC TTG CGC TCA GGA GGA GCA ATG-3 
TH 5’-TGT GTC CGA GAG CTT CAA TG-3’
5’-GGG CTG TCC AGT ACG TCA AT-3’
Iba1 5’-GTC CTT GAA GCG AAT GCT GG-3’
5’-CAT TCT CAA GAT GGC AGA TC-3’
NG2 5’-TTA CCT TGG CCT TGT TGG TC-3’
5’-GAT GAT CTG TTT GGC CTG CT-3’
PCNA 5’-TAA GTT GTC CCA GAC AAG CA-3’
5’-GCG ATC GTC AAA GGT TTA GT-3’
GFAP 5’-CAG AAG CTC CAA GAT GAA ACC AA-3’
5’-TCT CCT CCT CCA GCG ACT CAA C-3’
IGF-1 5’-TTG CGG GGC TGA GCT GGT GGA C-3’
5’-GCG GTG ACG TGC CAT TTT CTG TTC-3’
HGF 5’- TCT TGG TGT CAT TGT TCC TG -3’
5’-CCA TGG ATG CTT CAA ATA CA -3’
BDNF 5’-CGT GAT CGA GGA GCT GTT GG-3’
5’-CTG CTT CAG TTG GCC TTT CG-3’
GM-CSFRα 5’-ACT AGT ATG TGG CTG CAG AAT TTA CTT
TTC-3’
5’-GGT ACC TCA TTT CTG GAC CGG CTT CC-3’
IL-3Rα 5’-ACT AGT ATG GTT CTT GCC AGC TCT AC-3’
5’-GGT ACC TTA ACA TTC CAC GGT CAT AGG
G-3’
Metallothionein 2 5’-CAC AGA TGG ATC CTG CTC CT-3’
5’-GAG AAC CGG TCA GGG TTG TA-3’
Cu/Zn SOD 5’-TTC GAG CAG AAG GCA AGC GG-3’
5’-ATC CCA ATC ACA CCA CAA GC-3’
Bcl-xL 5’-CCT ATC TTG GCT TTG GAT CC-3’
5’-TTT CTT CTG GGG CTT CAG TC-3’
Bax 5’-TGC AGA GGA TGA TTG CTG AC-3’
5’-GAT CAG CTC GGG CAC TTT AG-3’
TNFα 5’-CCC AGA CCC TCA CAC TCA GAT-3’
5’-TTG TCC CTT GAA GAG AAC CTG-3’
IL-1β 5’-CAC CTT CTT TTC CTT CAT CTG T-3’
5’-GTC GTT GCT TGT CTC TCC TTG TA-3’
TH = tyrosine hydroxylase; PCNA = proliferating cell nuclear antigen;
GFAP = glial ﬁbrillary acidic protein; IGF-1 = insulin-like growth factor-
1; HGF = hepatocyte growth factor; BDNF = brain-derived neurotrophic
factor; Cu/Zn SOD = copper and zinc superoxide dismutases; TNFα =
tumor necrosis factor α;G M - C S F R α = granulocyte macrophage colony-
stimulating factor receptor α;I L= interleukin.
Green (Roche Diagnostic Japan, Tokyo, Japan). PCR condi-
tions were as follows: 50◦Cf o r2m i n ,9 5 ◦Cf o r1 0m i n ,
followed by 40 cycles of 95◦C for 15 s and 60◦Cf o r1m i n .
All gene-speciﬁc mRNA expression values were normalized
against β-actin mRNA. The primer sequences for each gene,
as well as the sizes of their products, are listed in Table 1.
Immunoblotting
The ventral midbrain from the opposite side of the tis-
sue used for qRT-PCR (n = 7) was immediately homog-
enized with SDS solution in 10 volumes of Laemmli’s
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Table 2. Primary antibodies used in this study
Antigen Antibody Dilution Source
β-actin Mouse monoclonal 1:1000 Sigma
TH Sheep polyclonal 1:500 Gene tex
TH Rabbit polyclonal 1:500 abcam
Iba1 Rabbit polyclonal 1:500 Wako
NG2 Mouse monoclonal
(132.39)
1:500 Chemicon
GFAP Rabbit polyclonal 1:500 SHIMA Laboratories
CD11b Mouse monoclonal
(MRC OX42)
1:250 Serotec
Bcl-xL Mouse monoclonal 1:100 Transduction
Laboratories
TNF-α Rabbit polyclonal 1:500 Santa Cruz
GM-CSFRα Rabbit polyclonal 1:500 Santa Cruz
IL-3Rα Rabbit polyclonal 1:500 Santa Cruz
TNF-α Rabbit polyclonal 1:100 Bioworld Technology,
Inc.
IL-1β Rabbit polyclonal 1:100 Bioworld Technology,
Inc.
TH = tyrosine hydroxylase; GFAP = glial ﬁbrillary acidic protein; TNFα =
tumor necrosis factor α;G M - C S F R α = granulocyte macrophage colony-
stimulating factor receptor α;I L= interleukin.
sample solution containing 3% sodium dodecyl sulfate
(SDS).Thelysateswereelectrophoresed,transferredtonitro-
cellulosemembranes,andimmunoblottedwithantibodiesto
β-actin, tyrosine hydroxylase (TH), Iba1, NG2, and Bcl-xL
(Table 2). The immunoreaction was visualized using ni-
tro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phos-
phate, as described previously (Tanaka et al. 1998). Im-
munoreactive bands were analyzed by densitometry using
ImageJ 1.43u (Wayne Rasband, National Institute of Health,
Bethesda, ML). The densitometry data were standardized
with the internal standard β-actin.
Immunohistochemical staining
T h ep r i m a r ya n t i b o d i e sl i s t e di nT a b l e2w e r eu s e df o ri n -
direct immunoﬂuorescence staining (Yokoyama et al. 2006).
Brieﬂy, anesthetized rats were ﬁxed by transcardially perfus-
ing 4% paraformaldehyde containing 2 mM MgCl2 for 10
min, at a ﬂow rate of 80 mL/min. The dissected brains were
immersed in 15% sucrose in PBS at 4◦C overnight, rapidly
frozenindryicepowder,andslicedinto10-μmthickcoronal
sections at the substantia nigra level (from bregma 4.80 mm
to5.40mm).Thebrainsectionswereincubatedwiththepri-
mary antibodies followed by incubation with DyLight 488,
DyLight 549, and/or DyLight 649-labeled secondary anti-
bodies(JacksonImmunoResearchLaboratories,WestGrove,
PA). Hoechst 33258 (Sigma) was used for nuclear staining.
The immunostained specimens were observed with a Nikon
A1 confocal laser scan microscope (CLSM; Tokyo, Japan)
using 20× or 60× objective lenses. The area observed was
2.0–2.3 mm lateral from the midline.
Morphometric analysis
B r a i ns e c t i o n sp r o c e s s e da sd e s c r i b e da b o v ew e r et r i p l e -
immunostained with antibodies to Iba1, TH, and NG2. To
determine the area occupied by DArgic neurons, microglia,
and NG2 glia, and also their overlapping area in the SNpc of
the sections, micrographs were taken with the CLSM using
a2 0 × lens. The images were processed using Adobe Pho-
toshop CS5 Extended (Adobe Systems, San Jose, CA) and
ImageJ1.43u.First,theareawheretheDArgicneuronsinthe
SNpcweredistributedwasdemarcatedastheSNpc.Then,the
SNpc was further subdivided based on immunostaining for
TH, Iba1, and NG2. Overlapping staining for TH and Iba1,
TH and NG2, Iba1 and NG2, and Iba1-positive, but NG2-
negative,wereseriallydetermined(seeFig.6).Datafromﬁve
shamorsix6-OHDA-treatedratswerestatisticallyanalyzed.
Primary cultures
Rat primary microglial cultures were prepared (Tanaka et al.
1998). Brieﬂy, whole forebrains from neonatal rats were dis-
sected out and dissociated into individual cells with a nylon
bagwith160μmpores.Thedissociatedcellswereculturedas
a mixedglialcellculture in 75 cm2 ﬂasks with 10% foetalcalf
serum-supplemented Dulbecco’s modiﬁed Eagle’s medium.
Eleven or 14 days later, microglial cells were obtained from
the mixed glial culture. The purity of the microglial culture
was >99%, as determined by immunocytochemical staining
using antibodies to GFAP and Iba1. For immunocytochem-
ical detection of cytokine receptors, the cells were seeded
ontopoly-L-lysine-coatedglasscoverslipsplacedinfour-well
culture plates, and then immunostained for GM-CSF and
IL-3 receptors, as described above. Micrographs were taken
with conventional optics using an Olympus BX-52 (Olym-
pus, Tokyo, Japan). qRT-PCR to detect microglial mRNAs
was performed in the same way as described above.
Statistical analysis
Numerical data expressed as means± SEM were statistically
analyzedusingInStat3software(GraphPadSoftware,LaJolla,
CA). Statistical signiﬁcance was assessed with one-way anal-
ysis of variance (ANOVA) and Tukey’s post hoc test.
Results
Ameliorative effects of the cytokine mixture
on motor function in 6-OHDA-induced
Parkinsonian rats
The rats that received bilateral administration of 6-OHDA
into the striatum did not move smoothly, and had difﬁculty
in eating and drinking. Such motor dysfunction was appar-
ent 6 h after 6-OHDA administration. As a result, rat body
weights only minimally increased 7 days after 6-OHDA ad-
ministration (Fig. 1A). After this time point, however, the
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Figure 1. Effects of subcutaneous injection of the cytokine mixture on 6-OHDA-induced Parkinsonian rats. 6-OHDA was bilaterally administered into
the striatum. +Saline or +Cytokine indicate 6-OHDA-administred rats with subcutaneous injection of saline or cytokine, respectively. Subcutaneous
injection of the cytokine mixture was started 1 day after 6-OHDA administration, and repeated seven times (once per day). (A) Body weight change
during the course of 2 months after 6-OHDA administration; n = 21, 21, 14, 7, and 7, at 0, 1, 4, 6, and 8 weeks, respectively, after 6-OHDA
administration. (B) Motor function was evaluated by rota-rod test. (C) DA content in the striatum was determined by HPLC. The bilateral data were
averaged and expressed as means ± SEM. (D) Levels of mRNAs encoding TH, Iba1, and NG2 in the SNpc at 1 week from seven rats, as determined by
qRT-PCR. (E) Representative immunoblot data (n = 4) showing TH, Iba1, NG2, and β-actin protein level at 1 week. (F) Densitometric analyses of the
immunoblot data expressed as means ± SEM.
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6-OHDA-lesionedratsthatreceivedthecytokinemixturein-
jection (cytokine group) had increased body weight, nearly
equivalent to the control animals’ (sham group) body
weights, and the body weights of the cytokine group rats
were signiﬁcantly greater than the lesioned rats that received
saline injection (saline group). The rota-rod test revealed
marked motor dysfunction of the 6-OHDA-treated groups
at 1 week (Fig. 1B). However, the cytokine group recovered
motor function at 4 weeks and later. The sham group had
gradually declining motor function, probably due to their
increasing bodyweights. Consequently, there were no dif-
ferences in motor function between the sham and cytokine
groups at 8 weeks.
DA levels were measured by HPLC in the striatum. Ap-
proximately 15 μg/mg tissue weight of DA was detected in
thestriatumoftheshamgroup,butlessthan3μg/mgDAwas
present in the 6-OHDA-treated rats (Fig. 1C). This marked
decrease in DA content may underlie the motor dysfunction
of the 6-OHDA-treated rats. However, DA contents of the
cytokine group increased to 8 μg/mg or more, at 30 days or
later.
Total RNA was prepared from the ventral midbrain con-
tainingtheSNpcandthenreversetranscribedintocDNAfor
qRT-PCR (Fig. 1D). Although 6-OHDA administration de-
creased the amount of mRNA encoding the rate-limiting en-
zymeforDAsynthesisTH,themRNAlevelwashigherinthe
cytokine group than in the saline-treated group (Fig. 1Da).
mRNAs for the microglia marker Iba1 and the oligoden-
drocyte progenitor cell marker NG2 chondroitin sulphate
proteoglycan (NG2) increased in the cytokine group.
Protein samples were prepared at 7 and 30 days after 6-
OHDA treatment and used for immunoblotting to estimate
the amount of TH, Iba1, and NG2 at the protein level in
the SNpc. Representative results from four separate sam-
ples are shown in Fig. 1E. β- a c t i nw a su s e da sa ni n t e r n a l
standard. The protein bands from seven separate samples
were analyzed by scanning densitometry. Fig. 1F shows that
the TH protein decreased in the saline-treated group com-
pared with the sham group (Fig. 1Fa). Iba1 protein tended
to increase in the cytokine group at 7 days, but the level re-
turned to the sham level at 30 days (Fig. 1Fb). NG2 protein
was signiﬁcantly reduced at 30 days in the cytokine group
(Fig. 1Fc).
Expression of GM-CSF and IL-3 receptors in
neurons and microglia
AntibodiestoGM-CSFreceptorα (GM-CSFRα)andIL-3re-
ceptor α (IL-3Rα)wereusedincombinationwithantibodies
forTH,andamarkerformicroglia,CD11b,toinvestigatelo-
calizationofthesereceptorsintheSNpc(Fig.2).GM-CSFRα-
immunoreactivity was localized both in CD11b+ microglia
and the TH+ DArgic neurons (Fig. 2A). However, some
microglia appeared to express the receptor more strongly
than neurons. IL-3Rα immunoreactivity was also localized
in both microglia and DArgic neurons (Fig. 2B), but this
immunoreactivity was stronger in the neurons than in mi-
croglia. Primary cultured microglial cells expressed both re-
ceptors (Fig. 2C, D). mRNAs encoding these receptors were
evaluated by qRT-PCR. Both mRNAs were detected in the
ventral midbrain (Fig. 2E). Only GM-CSFRα-mRNA sig-
niﬁcantly increased in response to cytokine injection in the
6-OHDA-treated rats. This increase may imply that GM-
CSFR expression is regulated in a positive-feedback man-
ner, while IL-3R expression may likely be in a negative-
feedback manner. Therefore, when simultaneously injected,
GM-CSF might more effectively work than IL-3. Cultured
microglial cells also expressed both mRNAs (Fig. 2F). Given
the high level of expression of GM-CSFRα-mRNA in the
cultured microglia, it is likely that the main source of GM-
CSFRα-mRNA in the ventral midbrain is microglia. On the
other hand, DArgic neurons may be the main source of
IL-3Rα-mRNA.
Increased expression of Bcl-xL in DArgic
neurons in the SNpc of the cytokine-injected
rats
BothGM-CSFandIL-3havebeenreportedtoincreasetheex-
pression of antiapoptotic factors belonging to the Bcl-2 fam-
ily in isolated neurons (Wen et al. 1998; Huang et al. 2007;
Schabitz et al. 2008). Immunohistochemical staining with
antibodies to Iba1, TH, and Bcl-xL revealed that Bcl-xL
immunoreactivity was localized to capillary-like structures
(yellow arrowheads) in and around the SNpc in a sham rat
(Fig.3A).Bcl-xL-immunoreactivitywassimilarlylocalizedin
a saline-injected Parkinsonian rat, although the immunore-
activity was markedly suppressed (Fig. 3B). By contrast,
strongBcl-xL-immunoreactivitywaslocalizedtoDArgicneu-
rons of a cytokine-injected rat (Fig. 3C, blue arrowheads).
Notethattheactivatedmorphologyofmicrogliawasfoundin
the SNpc, only in the ipsilateral side of the 6-OHDA-treated
rats. Furthermore, immunoreactivity at a similar level was
observed in DArgic neurons in the contralateral SNpc of the
cytokine-injected rat, where microglia display resting ram-
iﬁed morphology (Fig. 3D). qRT-PCR showed a signiﬁcant
increase of Bcl-xL-mRNA in the cytokine group (Fig. 3E),
and the proapoptotic factor Bax-mRNA did not signiﬁcantly
changeamongthethreegroups(Fig.3F).Incomparisonwith
the mRNA data, Bcl-xL protein was not increased in the cy-
tokine group compared with the sham group. However, the
Bcl-xL protein was markedly decreased in the saline group
(Fig. 3G). These data suggest that 6-OHDA administration
accelerates degradation of Bcl-xL protein and that the cy-
tokine injection increased the transcription of Bcl-xL mRNA
in DArgic neurons.
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Figure 2. Expression of receptors for GM-CSF and IL-3 in the SNpc and primary cultured microglia. (A) Immunoreactivity of GM-CSFRα was localized
to microglial cells (yellow arrowheads) and DArgic neurons (blue arrowheads). Microglial cells were identiﬁed with anti-CD11b antibody (OX42) and
DArgic neurons with anti-TH-antibody. (B) Immunoreactivity of IL-3Rα was also localized to microglial cells (yellow arrowheads) and DA neurons
(blue arrowheads). (C and D) Primary cultured microglial cells expressing GM-CSFRα (C)a n dI L - 3 R α (D). (E) qRT-PCR revealed the presence of mRNAs
encoding the receptors. The data from seven rats are expressed as means ± SEM. (F) The receptor mRNAs were expressed in the primary microglia
culture. The data from 4 separate cultures are expressed as means ± SEM.
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Figure 3. Antiapoptotic factor Bcl-xL expression in the SNpc. (A–D) Representative immunohistochemical data showing expression of Bcl-xL protein
in the SNpc of sham, saline, and cytokine group at 1 week after 6-OHDA administrations. Localization of Bcl-xL immunoreactivity was only found
in the cytokine-injected rat SNpc. The upregulated Bcl-xL expression was also found in the contralateral SNpc, where microglia display the resting
phenotype. (E) Bcl-xL mRNA level was elevated in the cytokine group at 1 week, as revealed by qRT-PCR (n = 7). (F) Bax-mRNA did not show marked
differences among the three groups. (Ga) Bcl-xL protein was strongly detected in the cytokine group by immunoblotting, while its expression was
suppressed in the saline group. Representative data from four rats of each group are shown. (Gb) Densitometric analysis showed a signiﬁcant drop in
Bcl-xL protein expression in the saline group. Data from seven rats of each group are expressed as means ± SEM.
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Phenotypic changes of microglia in response
to the cytokines
It has been shown previously that primary cultured rat mi-
croglial cells change their morphology in response to GM-
CSF and IL-3 (Fujita et al. 1996). To determine whether
primary microglial cells change their functional phenotypes
in response to the cytokines, total RNA was prepared from
microglial cells cultured in the presence or absence of the
cytokines, and mRNA levels encoding insulin-like growth
factor-1 (IGF-1), hepatocyte growth factor (HGF), IL-1β,
and TNFα were determined (Fig. 4A). Both IGF-1 and HGF
ameliorate 6-OHDA-induced Parkinsonism (Clarkson et al.
2001; Koike et al. 2006; Ebert et al. 2008). mRNAs encod-
ing the neuroprotective factors IGF-1 and HGF increased,
and mRNAs for the detrimental proinﬂammatory cytokines
decreased in the presence of the both cytokines. Thus, this
resultindicatesthatGM-CSFandIL-3strengthenedtheneu-
roprotectivenatureofculturedmicroglia.Similarresultswere
obtained in in vivo experiments (Fig. 4B). IGF-1 and HGF-
mRNAs increased more signiﬁcantly in the ventral midbrain
of the cytokine group than in the ventral midbrain of the
saline group. IL-1β and TNFα mRNAs markedly increased
i nt h es a l i n eg r o u p ,b u tt h el e v e l si nt h ec y t o k i n eg r o u p s
returned to the sham level. Immunohistochemical staining
using anti-IL-1β and TNFα antibodies showed the positive
immunostaining of the proinﬂammatory cytokines in DAr-
gic neurons (blue arrowheads) and microglia (yellow ones)
(Fig.4C–F).Inspiteofsuchfunctionaldifferences,microglial
cells in the SNpc displayed amoeboid morphology in both
the 6-OHDA-treated groups.
Contact between neurons and glia
Detailed morphological observation using 3D-constructed
images taken by CLSM revealed the intimate contacts be-
tweenneuronsandglialcellsandthepresenceofIba1+/NG2+
cells (Fig. 5). The brain section in Figure 5 was from a
cytokine-injectedrat that was immunostainedwith antibod-
ies to Iba1, NG2, and TH. The merged image of Iba1 and
NG2 immunoreactivities (Fig. 5D) shows the presence of
Iba1+/NG2+ cells,whichhavebeendescribedasaneuropro-
tective cell type (Kitamura et al. 2010). Activated microglial
cells have long been described to intimately attach to dam-
agedneuronsandremovesynapticinputs.Thisphenomenon
is called “synaptic stripping” and is supposed to be neuro-
protective (Cullheim and Thams 2007; Trapp et al. 2007).
The presence of synaptic stripping by immunoﬂuorescence
would be evident when the green ﬂuorescence representative
of Iba1-immunoreactivity is merged with the red ﬂuores-
cenceofTH-immunoreactivity,thusproducingyellowcolor.
Indeed,themergedyellowcolorisevidentintheregionwhere
microglia and DArgic neurons intimately attach in Fig. 5E.
In addition, NG2 glia also appeared to closely attach to DAr-
gicneurons.Thisisseenwhengreenimmunoﬂuorescenceof
NG2 is merged with the red immunoﬂuorescence of DArgic
neurons;thecontactregionsofNG2gliaandDArgicneurons
appear as orange regions (Fig. 5F). The attachment of NG2
glia to DArgic neurons appeared more frequently than that
of microglia.
Morphometric analyses of cell densities and
interactions between glial cells and DArgic
neurons
For the statistical evaluation of the cell types in the differ-
ent treatments, detailed morphometric analyses were con-
ducted using the CLSM images of Iba1, NG2, and TH im-
munoﬂuorescence. Because immunoblotting and qRT-PCR
was done on dissected ventral midbrain that not only con-
tained the SNpc, but also other regions, it was necessary to
employ immunohistochemical technique to analyze speciﬁc
reactions of cells selectively in the SNpc. The region contain-
ing TH-immunoreactivity was deﬁned as the SNpc region,
and the area was determined using ImageJ 1.43u software.
Similarly, areas containing TH, Iba1, and NG2 immunore-
activities were also independently measured. Furthermore,
the following overlapping stained areas were also measured:
TH/Iba1-double-positive areas (indicative of synaptic strip-
ping by microglia), Iba1+/NG2+-double-positive areas (in-
dicative of NG2+ microglia), Iba1−/NG2+ areas (indicative
of NG2 glia that are not microglia), and TH+/Iba1−/NG2+
areas (indicative of attachment of NG2 glia to DArgic neu-
rons). These areas were further divided by areas positive for
SNpc,TH,orIba1.Figures6A–Cshowexamplesofprocessed
pictures from these morphometric analyses.
Summaries of the results obtained from the sham group
(ﬁve rats) and the saline and cytokine groups (six rats)
are shown in Figures 7A–G. TH/SNpc data are indicative
of the number of surviving DArgic neurons in the SNpc
(Fig. 7A), which was comparable to the immunoblot and
RT-PCR data shown in Figure 1D–F. Cytokine injection sig-
niﬁcantly prevented DArgic neuronal loss. Iba1/SNpc is in-
dicativeofmicroglialactivation(Fig.7B).However,theIba1+
area in the SNpc was not markedly expanded, even in the
6-OHDA-treated rats, in spite of the presence of activated
microglia.Furthermore,therewasno differenceintheIba1+
area between the saline and cytokine groups. TH+Iba1/TH
is indicative of synaptic stripping (Fig. 7C), but there were
no signiﬁcant differences among the three groups. Total
NG2/SNpc is indicative of the degree of activation and/or
proliferation of NG2+ cells, which includes NG2+ microglia
(Fig. 7D). This index signiﬁcantly increased only in the cy-
tokine group. The level of Iba1+NG2/Iba1 signiﬁcantly in-
creased in the 6-OHDA-treated rats as described elsewhere
(Kitamuraetal.2010),bothinthesalineandcytokine-treated
groups (Fig. 7E), suggesting that NG2+ microglia do not
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Figure 4. Effects of cytokines on microglial cells in vitro and in vivo.( A) qRT-PCR revealed that cultured microglial cells have increased mRNAs encoding
IGF-1 (Aa) and HGF (Ab), while there is decreased mRNAs encoding IL-1β (Ac) and TNFα (Ad), when they were incubated with the cytokine mixture.
The in vitro data were obtained from four separate cultures and expressed as means ± SEM. (B) mRNAs encoding IGF-1 (Ba) and HGF (Bb) also
increased in tissue containing SNpc in response to the cytokine injection. By contrast, mRNAs for IL-1β (Bc) and TNFα (Bd) increased only in the saline
group. In vivo qRT-PCR was from seven rats and expressed as means ± SEM. (C–E)I L - 1 β immunoreactivity in the SNpc of sham (C), saline (D), and
cytokine (E) group at 1 week after 6-OHDA administrations. Rather strong IL-1β immunoreactivity was localized in neurons (blue arrowheads) and
microglia (yellow arrowheads) in SNpc of saline-injected rats. (F)T N F α immunoreactivity was found in microglial cells (yellow arrowheads) and in
neurons (blue arrowheads) in SNpc of saline-injected rats.
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Figure 5. Reaction of cells expressing Iba1 and NG2 in the SNpc of a cytokine-injected 6-OHDA-administred rat, as shown in a 3D-reconstructed
immunohistochemical picture. Seventeen 0.25-μm thick optical sections were reconstructed. (A, B,a n dC) Images show Iba1+ (green), NG2+ (pink),
TH+ (red) cells, respectively. (D)I b a 1 +/NG2+ cells, denoted with arrowheads, were present, displaying microglia-like morphology. (E)I b a 1 + microglial
cells often are closely attached to TH+ DA neurons (arrowheads), appearing as a merge of green and red colors to produce the yellow color. (F)
Attachment of NG2+ cells to TH+ DA neurons. Color of NG2+ cells was changed to green, and then merged with red colors. A closely attaching
region between DA neurons and NG2+ cells is displayed as an orange color (arrowheads).
contributetothecytokine-inducedDArgicneuronalsurvival.
The NG2 alone/SNpc index increased only in the cytokine
group (Fig. 7F), indicating that NG2 glia increased in num-
ber only in the cytokine group. TH+NG2 alone/TH index
also increased only in the cytokine group (Fig. 7G). These
morphometric data suggest that the increase of NG2 glial
cell number and their attachment to DArgic neurons may
underlie the neuroprotective effects of the cytokine mixture.
mRNA encoding proliferating cell nuclear antigen (PCNA, a
marker for proliferating cells) was markedly increased in the
cytokine group, which may be indicative of increased NG2
glial cell numbers rather than microglia.
Astrocytes and astrocyte-related
factors in the SNpc
Double-immunohistochemical staining using antibodies to
GFAP and TH was done to evaluate astrocytes in the SNpc
(Fig. 8). In the SNpc of the sham rats, GFAP immunoreac-
tivity was scarcely distributed (Fig. 8A). In contrast, GFAP
immunoreactivity was increased in the saline-injected rats
(Fig. 8B). However, GFAP immunoreactivity was notice-
ably reduced in cytokine-injected rats (Fig. 8C). In agree-
ment with these morphologic observations, GFAP-mRNA
wasalsoincreasedonlyinthesalinegroup.mRNAsencoding
BDNF,Cu/ZnSOD,andmetallothionein2,whichcouldmost
likely be from astrocytes, were increased only in the saline
group.
Discussion
This study demonstrated that subcutaneous administration
ofacytokinemixtureofGM-CSFandIL-3exhibitedmarked
neuroprotectiveeffectsagainst6-OHDA-inducedParkinson-
isminrats.Itisofclinicalrelevancethatthecytokineadmin-
istration was started one day after the 6-OHDA-treatment.
Thedoseofthecytokineswas10μg/kgbodyweight,whichis
comparable to the dose of GM-CSF or IL-3 typically used
for human cases to stimulate the bone marrow (Hocker
et al. 1993; Bastion et al. 1995). Based on these facts, the
cytokine mixture used in the present study may be clinically
applicable for the treatment of PD. Furthermore, given the
marked effects of this cytokine mixture in a model of PD,
it can also be employed as a pharmacological tool to deter-
mine therapeutic targets to prevent PD-associated neuronal
death.
Previously, it was shown that GM-CSF upregulates the ex-
pression of antiapoptotic factors belonging to the Bcl family
in neurons expressing GM-CSFR (Huang et al. 2007; Schab-
itz et al. 2008), which resulted in the prevention of neuronal
cell death. IL-3 was also shown to suppress neurodegenera-
tion through increased Bcl-xL expression (Wen et al. 1998).
In this study, subcutaneous injection of the cytokine mix-
ture induced DArgic neurons in 6-OHDA-lesioned brains
to upregulate Bcl-xL expression. This effect was indepen-
dent of activated microglia, because DArgic neurons in the
contralateral SNpc also upregulated expression of Bcl-xL,
as shown in Figure 3. This likely contributed to suppressed
DArgic neurodegeneration. The surviving neurons with el-
evated Bcl-xL expression then would affect the actions of
glial cells within their vicinity. Neurons fated to die may ac-
tivate microglial cells to accelerate neuronal degeneration,
while surviving neurons may activate neuroprotective at-
tributes of glial cells (Streit et al. 1999; Cullheim and Thams
2007).
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Figure 6. Morphometric analyses of TH+,I b a 1 +,a n dN G 2 + cells in the SNpc of sham, saline, and cytokine-treated rats. (A, B,a n dC) Images show
triple-immunostained SNpc of each group of rats (at 1 week) with antibodies to TH (red), Iba1 (green), and NG2 (pink) as merged pictures. Black and
white images were drawn from the original micrographs with individual colors, after SNpc regions were picked out, based on the distribution of the
TH+ DArgic neurons. TH/SNpc = ratio of TH+ region in the SNpc. Iba1/SNpc = ratio of Iba1+ region in the SNpc. TH+Iba1/TH = ratio of TH+/Iba1+
region in the TH+ region, an index of synaptic stripping by microglia. Total NG2/SNpc = ratio of NG2+ region in the SNpc. Iba1+NG2/Iba1 = ratio of
Iba1+/NG2+ region in the Iba1+ region, an index of the incidence of Iba1+/NG2+ cells. NG2 alone/SNpc = ratio of NG2+/Iba1− region in the SNpc,
an index of the incidence of NG2+ cells that do not express Iba1. TH+NG2 alone/TH = ratio of TH+/NG2+, but not Iba1+ region in the TH+ region,
an index of attached NG2+ cells, but not microglia, to neurons.
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Regardless of the cause of brain injury, microglial cells re-
spond to even minor pathologic events in the brain, evident
by morphologic changes such as enlargement of their cell
bodiesandshorteningoftheirramiﬁedprocesses(Kreutzberg
1996; Streit et al. 1999). 6-OHDA-treatment caused mi-
croglial activation with these types of morphologic changes.
However, it is notable that the activated morphology was
observed regardless of the survival of DA neurons, with or
without the cytokine mixture injection. Interestingly, many
studies have described the harmful effects of activated mi-
croglia on neurons (Mosley et al. 2006; Long–Smith et al.
2009; Tansey and Goldberg 2010); however, our results sug-
gest that this may not always be the case.
There are some controversies regarding the activation
of microglia (Liberatore et al. 1999; Henry et al. 2009;
Marinova–Mutafchieva et al. 2009). Is their activation the
cause or the result of DArgic neurodegeneration? Because
DArgic neurodegeneration induced by 6-OHDA is a rather
chronic process (Henry et al. 2009; Marinova–Mutafchieva
et al. 2009), it is conceivable that microglial activation may
i n ﬂ u e n c et h ef a t eo fD A r g i cn e u r o n se v e ni ft h eD A r g i cn e u -
rodegenerationprecedesmicroglialactivation.Infact,proin-
ﬂammatory cytokines, such as IL-1β or TNFα,a n dr e a c t i v e
oxygen species, such as NO or superoxide, which are pro-
ducedbymicroglia,havebeenimplicatedinthepathogenesis
of PD (McGeer and McGeer 2008; Long–Smith et al. 2009;
Yacoubian and Standaert 2009; Tansey and Goldberg 2010).
The ameliorative effects of the cytokine mixture may be
related to the functional changes of the activated microglia.
The cytokine injection decreased the expression of IL-1β or
TNFα in theSNpc of 6-OHDA-treatedrats and it simultane-
ously increased expression of IGF-1 and HGF. IGF-1 (Guan
etal.2000;Ebertetal.2008;)andHGF(Koikeetal.2006)have
been shown for its ameliorative effects of 6-OHDA-induced
rat Parkinsonism. Addition of GM-CSF and IL-3 to primary
microglial cell cultures induced similar expression spectra
of the proinﬂammatory cytokines and the neuroprotective
factors. Thus, the action of the cytokine mixture to alter
the microglial phenotype from a neurotoxic phenotype to a
neuroprotective one, could at least partly explain the ame-
lioration of 6-OHDA-induced Parkinsonism by the cytokine
mixture. Damaged DArgic neurons can cause microglial ac-
tivation through soluble factors, such as μ calpain (Levesque
et al. 2010), and other insoluble factors on the plasma mem-
brane (Sudo et al. 1998). Microglia activated by signals from
damaged neurons may produce harmful factors that further
contribute to neurodegeneration, or by phagocytizing the
dying neurons. However, when the neuronal damage is not
severe enough to induce neuronal death, microglia may be-
come neuroprotective and promote neuronal survival by re-
leasing various neuroprotective factors. This duality of func-
tion by microglia has long been proposed (Kreutzberg 1996;
Streitetal.1999;CullheimandThams2007),andagentsthat
change the microglial phenotype from destructive to pro-
tective have been sought for a long time as treatments for
neurological disorders. This cytokine mixture may have this
microglialphenotype-changingactivity.Thebeneﬁcialeffect
of this cytokine mixture may also be related to its ability to
increase the expression of Bcl-xL in neurons. This effect may
promote the survival of damaged neurons, activate the neu-
roprotective actions of surrounding microglia, and further
b o l s t e rn e u r o n a ls u r v i v a l .
Expression of NG2 by microglia may be another hallmark
of their activation (Yokoyama et al. 2006; Kitamura et al.
2010; Zhu et al. 2010). Although NG2+ microglia have been
reported to express a neuroprotective factor, GDNF (Kita-
mura et al. 2010), it appears that in the present scenario this
neuroprotective factor did not contribute to neuronal sur-
vival in the 6-OHDA-induced Parkinsonism model. This is
because NG2+ microglia were present following 6-OHDA
treatment without and with cytokine treatment.
6-OHDA-inducedneurotoxicityhasbeenattributedtoox-
idative stress (Glinka et al. 1997). Astrocytes have strong
antioxidant properties (Tanaka et al. 1999; Miyazaki et al.
2011), and activated astrocytes are known to prevent DArgic
neurodegeneration (Asanuma et al. 2010; Choudhury et al.
2011). Activated astrocytes were also evident in this study
and the expression of mRNAs encoding Cu/Zn SOD and
metallothionein 2, both of which play critical roles in sup-
pressing oxidative stress, were upregulated in parallel with
increased GFAP expression in the SNpc of the saline group.
However,theactivationofastrocytesandtheupregulationof
antioxidant factors did not lead to improved survival of neu-
rons.Furthermore,whenneurodegenerationwassuppressed
with the cytokine mixture, both astrocytic activation and the
expressionofantioxidativefactorswerealsosuppressed,sug-
gesting that astrocytes and the antioxidative factors do not
contributeto DArgicneuronal survivalin the presence of the
cytokines.
On the other hand, NG2 glia may contribute to the
survival of DArgic neurons. NG2 glia are abundantly dis-
tributedthroughoutthebrainandthespinalcord,represent-
ing 5–15% of nonneuronal cells (Staugaitis and Trapp 2009;
Trotter et al. 2010). Some of these cells are also oligodendro-
cyte progenitor cells. However, it is not clear so far how these
cells respond to neural injury in PD. As shown in the present
study,NG2gliaappearedtoincreaseinnumberandtoattach
intimately to damaged DArgic neurons in the SNpc in the
cytokine group. Elevation of PCNA-mRNA may be related
to the proliferation of NG2 glia. In contrast to astrocytes,
the increase in the occupying area by NG2 glia and their
attachment to DArgic neurons were prominent in the cy-
tokine group, and therefore, it is possible that NG2 glia elicit
neuroprotective effects under the inﬂuence of the cytokine
mixture. However, NG2 glia did not express receptors for
GM-CSF,andIL-3.NG2gliamayrespondtoIGF-1andHGF
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Figure 9. A summarized scheme based on the present data. 6-OHDA-induced DArgic neurodegeneration accompanies microglial activation. Without
the cytokine mixture injection, activated microglia (MG) release the proinﬂammatory cytokine IL-1β and TNFα, causing further damage to DA neurons,
and results in the formation of astrogliosis. Therefore, the activated microglia in this case can be considered as “Bad MG.” When the cytokine
mixture is injected, increased Bcl-xL expression suppresses DA neurodegeneration, and activated MG does not cause appreciable release of detrimental
proinﬂammatory cytokines, but neuroprotectants, such as IGF-1 and HGF. Therefore, they can be considered as “Good MG.” IGF-1 and HGF from
activated MG can cause activation and proliferation of NG2 glia.
releasedbymicroglia.IGF-1hasbeenshowntobecrucialfor
the survival of NG2 glial cells (Sundberg et al. 2010). NG2
glia express c-Met/HGF receptor, and HGF promotes NG2
glial proliferation (Ohya et al. 2007). In the present study,
the cytokine mixture was found to upregulate expressions of
IGF-1 and HGF in cultured microglia and in microglia in
the ventral midbrain. Therefore, the cytokine mixture may
stimulateNG2glialsurvivalandproliferationthroughIGF-1
and HGF, which is released by microglial cells in the SNpc of
the cytokine-treated rats.
Inconclusion,thisstudydemonstratedtheneuroprotective
effects of a cytokine mixture containing GM-CSF and IL-3.
A summary of our ﬁndings is shown in Figure 9. We pro-
pose that 6-OHDA administration into the striatum causes
DArgic neurodegeneration in the SNpc and accompanying
microglial activation (Fig. 9). The activated microglia pro-
duce proinﬂammatory cytokines that cause further chronic
neurodegeneration. This neurodegeneration may also cause
further activation of microglia, which in this scenario is not
neuroprotective. Thus, a vicious cycle of neuronal degenera-
tion occurs (Levesque et al. 2010). On the other hand, when
thecytokinemixtureisinjected,DArgicneuronsincreaseBcl-
xLexpression,andthus,theseneuronsavoiddegenerationin
the face of 6-OHDA toxicity. In this scenario, the microglia
become activated and display an activated morphology, sim-
ilar to that in the saline group, but in this case they suppress
proinﬂammatory cytokine expression. The microglia in the
cytokinemixture-treatedgrouphaveenhancedexpressionof
the neuroprotective factors IGF-1 and HGF. IGF-1 and HGF
enhances not only the viability of neurons but also the sur-
vival and production of NG2 glia, which can contribute to
neuronalsurvival.Therefore,itisproposedthatthiscytokine
mixturehasneuroprotectivepropertiesandcouldhelpinthe
treatment of PD.
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